Skip to main content
Premium Trial:

Request an Annual Quote

Sequana Earns Milestone Payment from Glaxo in Diabetes Research Project

Premium

LA JOLLA, Calif.--Genomics company Sequana Therapeutics here has earned a milestone payment from Glaxo Wellcome in recognition of its success in identifying certain regions of DNA that contain genes associated with noninsulin-dependent diabetes. "This is an important step toward finding the genes responsible for diabetes," commented Callum Bell, Sequana's project leader for diabetes research. "Combining Sequana's high-technology gene discovery platform with Glaxo Wellcome's expertise in the field of diabetes has permitted very rapid progress," he added.

"Our next steps will be to identify the gene or combination of genes that cause diabetes, and then to understand how the proteins these genes encode contribute to the disease," remarked Dan Burns, Glaxo Wellcome's project leader of the diabetes genetics team.

Filed under

The Scan

Single-Cell Sequencing Points to Embryo Mosaicism

Mosaicism may affect preimplantation genetic tests for aneuploidy, a single-cell sequencing-based analysis of almost three dozen embryos in PLOS Genetics finds.

Rett Syndrome Mouse Model Study Points to RNA Editing Possibilities

Investigators targeted MECP2 in mutant mouse models of Rett syndrome, showing in PNAS that they could restore its expression and dial down symptoms.

Investigators Find Shared, Distinct Genetic Contributors to Childhood Hodgkin Lymphoma

An association study in JAMA Network Open uncovers risk variants within and beyond the human leukocyte antigen locus.

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.